Abstract: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an ?1 blocker in combination.

Abstract: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Abstract: The subject invention provides CAI compounds and formulations thereof, and methods for their use in the localized treatment of non-life threatening diseases. Formulations of CAI compounds of the subject invention include CAI free base and CAI prodrug microcrystallines, microparticles, emulsions, and the like. The subject invention further provides methods for treating non-life threatening diseases using the CAI compounds of the invention (i.e., novel delivery systems and combination therapies) that are effective and are associated with little or no adverse side effects.

Abstract: An object of the present invention is to provide a composition for local anesthesia to be added to a local anesthetic drug, the composition showing a sustained local anesthetic effect and having high safety. The object is achieved by a composition for local anesthesia including a drug antagonistic to a systemic action of adrenaline, i.e., an ?2 receptor agonist. The ?2 receptor agonist can be added to a local anesthetic agent together with adrenaline or a salt thereof to reduce the amount of adrenaline to be added as compared to that of adrenaline or a salt thereof alone. As a result, a sustained local anesthetic effect is obtained and local anesthesia can be performed with high safety.

Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Abstract: Provided herein are methods of protecting all or a portion of the optic nerve fiber layer within the optic nerve/lamina cribrosa (ONLC) complex in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and protecting all or a portion of the optic nerve fiber layer within the ONLC of the individual. In a particular embodiment, the invention is directed to methods of treating glaucoma in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of an agent that results in crosslinking of collagen in the indiviudal's peripapillary sclera, thereby stiffening the individual's peripapillary sclera and treating the glaucoma in the individual.

Abstract: The use of low molecular weight amino alcohols in ophthalmic compositions is described. These compounds have been found to enhance the efficacy of anti-microbial preservatives.

Abstract: The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer.

Abstract: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.

Abstract: Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agent's cooling activity from inhibition when in the presence of a short-chain alcohol.

Abstract: The present invention provides a method of treating a corneal disorder comprising administering to a patient in need thereof a composition containing pharmaceutically effective amount of dioleoylphosphatidylglycerol and/or palmitoyloleoylphosphatidylglycerol and a pharmaceutically acceptable carrier.

Abstract: An aqueous eye drop comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and an organic amine (for example, aminoethylsulfonic acid or trometamol) or a salt thereof is useful as an eye drop for once a day administration for treating inflammatory diseases of the external segment or the anterior segment of the eyes, since such aqueous eye drop can maintain a therapeutically effective concentration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid in anterior aqueous humor for at least 24 hours by once a day administration.

Abstract: The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Abstract: This invention relates to methods for treating age-related macular degeneration, blindness or glaucoma using an iron-chelator SIH.

Abstract: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract: Ophthalmic compositions that comprise 0.1 ppm to 2 ppm of poly(hexamethylene biguanide); and 0.005 wt. % to 0.3 wt. % of a PEG-glycerol ester of general formula I wherein R1 is a C3-C8alkyl and R2 is H or a C1-C4alkyl; and x+y+z has an average value from 8 to 30. The invention is also directed to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.

Abstract: An ophthalmic composition that, despite containing alginic acid and/or a salt thereof, has improved tackiness during use and provides a satisfactory use feeling. The composition has an improved ability to remain on the eye mucosa. The ophthalmic composition contains (A) alginic acid and/or a salt thereof in combination with (B) hyaluronic acid and/or a salt thereof.

Abstract: A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects.

Abstract: The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.

Abstract: Stable aqueous solutions comprising concentrations of baclofen in the range of greater than 2.0 mg/mL up to about 10 mg/mL are disclosed. These solutions can be used as pharmaceuticals for parenteral or oral administration. The invention also provides methods of preparing said stable aqueous baclofen solutions.